We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00287781
First Posted: February 7, 2006
Last Update Posted: January 25, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Kern Medical Center
February 6, 2006
February 7, 2006
January 25, 2008
January 2002
Not Provided
Resolution of symptoms
Same as current
Complete list of historical versions of study NCT00287781 on ClinicalTrials.gov Archive Site
Improvement in 10 point pain score
Improvment in 10 point pain score
Not Provided
Not Provided
 
A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache
A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache
Migraine headaches have previously been shown to be responsive to intranasal lidocaine in a small study. Using a nebulizer to administer the drug would improve the feasibility of using the treatment. It would also spare the patient narcotics with their attendant side effects. Because of the potential for placebo effect a placebo control is necessary in this study.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Migraine Headache
Drug: Lidocaine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
April 2006
Not Provided

Inclusion Criteria:

  • Meets IHS criteria for migraine

Exclusion Criteria:

  • Pregnant
  • Breast feeding
  • Allergic to Lidocaine
  • Worst or first Headache
  • Abnormal neurological exam
  • Substance abuse within 6 months
  • Cardiac, liver or pulmonary disease
  • Participation n another study within 30 days
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00287781
#04028
Not Provided
Not Provided
Not Provided
Not Provided
Kern Medical Center
Not Provided
Principal Investigator: Rick McPheeters, DO FAAEM Kern Medical Center UCLA
Kern Medical Center
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP